NeOnc Technologies Holdings, Inc. · NASDAQ:NTHI

NeOnc Technologies — Investor Presentation (November 2026)

57 slides from NeOnc Technologies's investor presentation, Nov 17, 2026

  1. Slide 1: NeOnc Technologies Holdings Corporate Presentation

    NeOnc Technologies Holdings, Inc. Corporate Presentation Clinical - stage CNS therapeutics. Intranasal delivery designed to bypass the blood – brain barrier, with two platforms — NEO100 and NEO212 — in clinical development for primary brain tumors and brain metastases. NASDAQ: NTHI 179 patents (issu

  2. Slide 2: Our Team: Leadership, board & scientific advisors

    OUR TEAM Leadership, board & scientific advisors SENIOR MANAGEMENT Amir F. Heshmatpour CEO, Exec. Chairman & President Thomas Chen, MD, PhD Founder, CMO & CSO Josh Neman, PhD Chief Clinical Officer Keithly A. Garnett Chief Financial Officer David Choi, CPA Chief Accounting Officer BOARD OF DIRECTORS

  3. Slide 3: Disclaimer

    DISCLAIMER Important cautions regarding forward - looking statements This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities. The distribution may be restricted by law in certain jurisdictions and persons into whose possession thi

  4. Slide 4: Clinical development & pipeline

    CLINICAL PIPELINE Clinical development & pipeline Important disclaimer: this development & clinical pipeline is subject to regulatory approval, risks and uncertainties, and potential changes beyond ou r control. Clinical Development Drug Candidate Application Indication Preclinical IND Enabling* Pha

  5. Slide 5: NEO100 and NEO212 platforms

    5 NEO100 — Drug Delivery Platform (core technology) NEO212 — Drug Conjugation Platform (built on NEO100) PLATFORM Two platforms, one enabling technology: NEO100's BBB penetration powers both • Conjugates NEO100 to established cytotoxic agents • Inherits NEO100's BBB - penetrating chemistry as the de

  6. Slide 6: NEO100 ultra-pure perillyl alcohol, nose-to-brain

    PLATFORM 1 · INTRANASAL DELIVERY NEO100 — ultra - pure perillyl alcohol, delivered nose - to - brain Sources: NEO100 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. NEO100 - 01 (N

  7. Slide 7: The starting line matters: U.S. burden

    THE STARTING LINE MATTERS · U.S. BURDEN IDH1 - mutant survival is quoted from diagnosis — in years IDH1 - mutant grade 3 – 4 astrocytomas are the “long - survivor” subset of glioma — but that survival is measured from initial diagnosis, and the treated U.S. population is large and growing. 26,480 /

  8. Slide 8: The clock resets at recurrence

    THE CLOCK RESETS At recurrence, prognosis collapses to 6 – 9 months — grade 3 and 4 High - grade gliomas virtually always recur despite maximal therapy. Once the tumor progresses after radiation and temozolomide, the survival clock no longer runs from diagnosis — it restarts at recurrence. FROM DIAG

  9. Slide 9: The Platform: NEO100

    THE PLATFORM NEO100: ultra - pure perillyl alcohol, delivered nose - to - brain Ultra - pure, patented POH NEO100 is a pharmaceutical - grade form of perillyl alcohol (POH), a natural monoterpene from citrus and peppermint oils. Proprietary synthesis Manufactured via a patented crystalline intermedi

  10. Slide 10: Mechanism of action

    MECHANISM OF ACTION NEO100's proposed mechanism of action in resistant tumors Sources: NEO100 is an investigational product candidate; it has not been approved by the FDA or any other regulatory authority and its sa fety and efficacy have not been established. Garcia DG et al., Mol Cell Biochem 2010

  11. Slide 11: NEO100 proposed mechanism in resistant tumors

    MECHANISM OF ACTION NEO100's proposed mechanism of action in resistant tumors In preclinical models, NEO100 is proposed to act on resistant glioma through three convergent mechanisms: Second - line rationale: by inducing ER stress and inhibiting Na ⁺ /K ⁺ - ATPase while down - regulating RAS, NEO100

  12. Slide 12: Phase 1 foundation: well tolerated, early survival signal

    PHASE 1 — FOUNDATION Intranasal NEO100 was well tolerated, with an early survival signal 1. Trial design Multi - center U.S. study, n = 12; recurrent GBM after RT + temozolomide; continuous intranasal dosing 384 – 1,152 mg/day (4 × /day) until progression. 3. Safety Generally, well tolerated at the

  13. Slide 13: Phase 2a objectives

    PHASE 2a — OBJECTIVES What the study set out to show in recurrent disease PRIMARY OBJECTIVE & ENDPOINT SECONDARY OBJECTIVES • Overall survival (OS) and landmark OS rates • Objective response & duration (RANO 2.0) • Safety and tolerability Sources: NEO100 is an investigational product candidate; it h

  14. Slide 14: Key figures: 6-month PFS

    Key figures 6 - month PFS (KM) 48. 9 % 95% CI 26.3 - 68.1 vs 20% SOC ( † 11.3) p = 0. 0 0 47 ض significant Clock origin Recurrence — NEO100 first dose (C1D1) At recurrence: the entire PFS curve is measured from first dose at recurrence (study day 1) — not from initial diagnosis. Sources: NEO100 is a

  15. Slide 15: Time on treatment swimmer plot

    PHASE 2a · TIME ON TREATMENT AT RECURRENCE Swimmer plot — Durable tail past 20 months from recurrence (first dose) Reading the plot Each bar = time on study from first dose at recurrence for each patient , colored by RANO 2.0 best response. ᶺ = progression (RANO 2.0) ظ = death → = still on treatment

  16. Slide 16: Survival summary

    Survival summary Deaths / N 12 / 24 Median OS (KM) 26. 09 months OS at 6 months 86.7% ( 64.3 - 95.5 ) OS at 12 months 6 0.9 % ( 36.4 - 78.4 ) OS at 24 months 54.1 % ( 29.5 - 73.4 ) ORR (RANO 2.0) 12.5 % At recurrence: the entire OS curve runs from first dose at recurrence (study day 1) — median 26.

  17. Slide 17: RANO 2.0 response & imaging

    RANO 2.0 RESPONSE & IMAGING Disease control, with radiographic response 8.3% 58.3% 33.3% 66.7% disease control Partial Response 3/24 · 12.5% Stable Disease 13/24 · 54.2% Progressive Disease 8/24 · 33.3% RANO 2.0 best response (N=24) 55% long - term survivors (16 / 29, Phase 1+2) surviving > 1 year 2

  18. Slide 18: The differentiation: recurrent grade 3-4

    THE DIFFERENTIATION Recurrent grade 3 – 4 is an open failure — NEO100's target Implication Grade 3 – 4 result Grade 3 – 4 studied? Trial (agent) Recurrent grade 3 – 4 unaddressed Not studied (mPFS 27.7 mo in grade 2) No — grade 2 only INDIGO (vorasidenib) Grade 4 remains an open failure No benefit i

  19. Slide 19: Conclusions: Phase 2a

    CONCLUSIONS Phase 2a: primary endpoint met — survival is the standout signal 48.9% PFS - 6 (RANO 2.0, KM) primary endpoint MET vs H ₀ ≤20% · p=0.0047 26.09 mo median overall survival after recurrence vs 6 - 9 months current salvage benchmark 60.9% alive at 12 months OS - 12 (95% CI 36.4 – 78.4) Dura

  20. Slide 20: Next steps: proposed registrational Phase 3

    NEXT STEPS Proposed registrational Phase 3 intended to seek Accelerated Approval (subject to FDA) The regulatory goal Accelerated Approval → traditional registrational approval, in one pivotal trial. Per FDA's Dec 2024 guidance, a single adequate & well - controlled trial can support Accelerated App

  21. Slide 21: NEO212 drug conjugation platform

    PLATFORM 2 · DRUG CONJUGATION NEO212 — built on NEO100, aimed at TMZ resistance Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. Chen TC et al., Cancer Lett 2015;35

  22. Slide 22: The TMZ ceiling

    Key Trial Context OS - 12 (%) Median OS ( mo ) Therapy REGOMA (~20%); EORTC 26101 (~30 – 35%) ~20 – 35% 5.6 – 8.6 CCNU ( lomustine ) alone BRAIN Trial ~38 – 43% ~9.2 Bevacizumab (Avastin) alone EORTC 26101 ~35 – 40% ~9.1 CCNU + Bevacizumab* EF - 11 ~20 – 25% ~6.6 TTFields alone THE TMZ CEILING Temoz

  23. Slide 23: The Molecule: NEO212

    THE MOLECULE NEO212: brain - optimized temozolomide bioconjugate Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. Chen TC et al., Cancer Lett 2015;358(2):144 – 151.

  24. Slide 24: Preclinical resistance data

    PRECLINICAL — RESISTANCE Results suggest NEO212 degrades MGMT and overcomes TMZ resistance in GBM Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. Chen TC et al., C

  25. Slide 25: Preclinical brain delivery

    PRECLINICAL — BRAIN DELIVERY NEO212: results suggest enhanced brain delivery and antitumor activity in TMZ - resistant GBM Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been estab

  26. Slide 26: NEO212 mechanism of action

    MECHANISM OF ACTION NEO212 proposed mechanism of action in resistant tumors Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. Chen TC et al., Cancer Lett 2015;358(2)

  27. Slide 27: Program snapshot: NEO212

    PROGRAM SNAPSHOT NEO212: novel alkylating therapy in clinical development for brain tumors Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. Chen TC et al., Cancer L

  28. Slide 28: Phase 1 design

    Total Subjects MGMT Status Tumor Type 3 N=1, Not applicable Squamous NSCLC - to - Brain Metastasis Cohort 1 (170mg/day) N=2 Methylated GBM IDH1 - wildtype 3 N=2 Methylated, N=1 Unmethylated GBM IDH1 - wildtype Cohort 2 (220mg/day) 3 N=1, Not applicable Esthesioneuroblastoma - to - Brain Metastasis C

  29. Slide 29: Phase 1 pharmacokinetics

    Cohort 5 (810 mg/QD) Cohort 4 (610 mg/QD) Cohort 3 (400 mg/QD) Cohort 2 (220 mg/QD) Cohort 1 (170 mg/QD) 2 3 3 3 3 N (evaluable) 3.25 16.8 12.19 2.52 1.94 Mean Peak AIC (ng/mL) 0 – 36.0 0 – 120.0 0 – 117.0 0 – 47.0 0 – 49.6 AIC Range (ng/mL) 6.96 13.83 2.04 0.07 0.17 Mean Peak PA (ng/mL) 0 – 43.6 0

  30. Slide 30: NEO212 vs TMZ brain-adjusted exposure

    Fig . 4 Representative TMZ ( F ), MTIC ( E ), and AIC ( Ƒ ) concentra - tion - time profiles from a patient who received 200 mg of TMZ . Solid and dashed lines , best - fit curves from the model - estimated parameters . NEO212 TMZ Brain - adjusted exposure NEO212 vs TMZ 200 mg/m² (Cycle 2+) Brain -

  31. Slide 31: Haematology: no meaningful myelosuppression

    PHASE 1 — HAEMATOLOGY No clinically meaningful myelosuppression observed in Phase 1 Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. NEO212 Phase 1 dose - escalatio

  32. Slide 32: Hepatic & renal safety

    PHASE 1 — HEPATIC & RENAL No hepatic or renal/urinary toxicity signal observed in Phase 1 Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. NEO212 Phase 1 dose - esc

  33. Slide 33: Phase 1 safety: MTD cohort key learnings

    Brain - adjusted exposure NEO212 vs TMZ 200 mg/m² (Cycle 2+) Brain - adjusted relative (3x BBB - permeable) Relative Exposure compared to TMZ TMZ total over 5 days (mg) NEO212 total 5 - day dose (TMZ - equivalent, mg; conversion ratio = 0.521) NEO212 total over 5 days (mg) NEO212 (mg/day) 0.73 0.25

  34. Slide 34: Antitumor activity in Phase 1

    PHASE 1 — ANTITUMOR ACTIVITY Antitumor activity observed in Phase 1 Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. NEO212 Phase 1 dose - escalation study in astro

  35. Slide 35: Partial response in recurrent GBM

    PHASE 1 — CASE 1 Partial response in recurrent IDH1 wild - type, MGMT - methylated GBM Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. NEO212 Phase 1 dose - escala

  36. Slide 36: Lung-to-brain metastasis case

    PHASE 1 — CASE 2 Lung - to - brain metastasis — 55 months since diagnosis, last 16 months on NEO212 Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. NEO212 Phase 1

  37. Slide 37: NEO212 next steps and Accelerated Approval strategy

    NEO212 — NEXT STEPS Proposed next steps and Accelerated Approval strategy Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. This slide contains forward - looking sta

  38. Slide 38: NEO212 development strategy

    NEO212 — DEVELOPMENT STRATEGY Phase 1 data informing a proposed Phase 2 strategy in TMZ - resistant GBM and brain metastases Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been est

  39. Slide 39: Why it matters

    WHY IT MATTERS NEO100 and NEO212: impact and significance Sources: NEO100 and NEO212 are investigational product candidates. Neither has been approved by the FDA or any other regulatory author ity , and their safety and efficacy have not been established. NEO100 — NEO100 - 01 (NCT02704858) Phase 2a,

  40. Slide 40: The opportunity

    THE OPPORTUNITY NeOnc's positioning in refractory neuro - oncology Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. This slide contains forward - looking statements

  41. Slide 41: Contact Us

    Contact Us Company Contact NeOnc Technologies Holdings, Inc. 23975 Park Sorrento, Suite 205 Calabasas, CA 91302 Tel +1 (818) 470 - NTHI Info@neonc.com · www.neonc.com Investor Relations Jon Nugent Communications Jon Nugent — President & CEO jonnugent.com · jon@jonnugent.com 205 - 566 - 3026 THE FUTU

  42. Slide 42: Appendix

    Appendix

  43. Slide 43: Senior Management Team

    LEADERSHIP Senior Management Team Our management team possesses significant experience in capital markets, with a track record of building shareholder value in cl inical biotech companies. Amir F. Heshmatpour CEO, Executive Chairman & President Mr. Heshmatpour served on NeOnc Technologies Holdings,

  44. Slide 44: Board of Directors

    GOVERNANCE Board of Directors Also serving Amir F. Heshmatpour CEO, Exec. Chairman & President Thomas Chen, MD, PhD Founder, CMO & CSO Victoria Medvec, PhD Compensation Committee Chair 20+ years as CEO of Medvec & Associates, advisory firm servicing more than a third of Fortune 100. Advising on regu

  45. Slide 45: Scientific Advisory Board

    ADVISORS Scientific Advisory Board Our Scientific Advisory Board provides objective perspective and guidance in product development, clinical trials, regulatory co mpliance, and biotech commercialization strategies. Henry S. Friedman, MD Chair, SAB Senior neuro - oncologist at Duke and deputy direct

  46. Slide 46: Company overview & investment highlights

    COMPANY OVERVIEW Company overview & investment highlights Founded in 2023, NTHI is a clinical - stage life sciences company. Focused on development & commercialization of central nervous system (CNS) therapeutics. Platform for novel drug candidates & delivery tech. Designed to address the persistent

  47. Slide 47: Intranasal chemotherapy strategy

    STRATEGY Intranasal chemotherapy designed to bypass the blood - brain barrier and target brain tumors Direct brain access: Intranasal delivery is designed to enable small - molecule therapeutics to bypass the BBB via the olfactory and trigeminal nerves, reaching the brain through the CSF. Non - inva

  48. Slide 48: Market need

    MARKET NEED The Need ~1 million Americans living with a primary brain tumor ~26% of all brain & CNS tumors are malignant #1 leading cause of cancer - related death in children (ages 0 – 14) 107,100 new primary brain & CNS tumors expected in the U.S. in 2025 ≈4,800 in children (ages 0 – 19) 18,330 de

  49. Slide 49: Pediatric brain cancer

    PEDIATRIC Pediatric Brain Cancer The Need #1 Brain tumors are the leading cause of cancer - related death among children (ages 0 – 14) and the most common solid tumor of childhood. ~4,800 children & adolescents (ages 0 – 19) are diagnosed with a primary brain tumor in the U.S. each year. ~40% Pediat

  50. Slide 50: Primary brain tumors and the IDH1 divide

    PRIMARY BRAIN TUMORS · WHO CNS5 (2021) Primary brain tumors and the IDH1 divide Primary brain tumors start in the CNS itself. Adult - type diffuse gliomas are the most common malignant kind — and since WHO 2021 they are defined first by IDH mutation status , not by appearance alone. IDH1 status spli

  51. Slide 51: Unmet need: the challenge

    UNMET NEED The Challenge While the FDA has approved many drugs for treating malignant glioblastomas (GBM), survival rates remain low with no significant improvement in prognosis over the past 50 years. Lack of progress primarily due to natural resistance mechanisms that limit efficacy of GBM treatme

  52. Slide 52: Versatility of NEO100

    VERSATILITY NEO100 has potential applications across clinical and commercial settings (investigational) Designed to act as a regulator for neurologic pathways associated with tumor cell growth. When delivered intranasally, its small molecular size is designed to allow it to bypass the blood - brain

  53. Slide 53: Clinical trial sites footprint

    FOOTPRINT Clinical Trial Sites Pending Sites Penn State Washington University Johns Hopkins Harvard / Mass General Hospital New York University Tampa General University of South Carolina Northwestern University Beverly Hills Cancer Center University of Vermont Westchester Medical Center Michigan Uni

  54. Slide 54: Global market outlook & drivers

    MARKET Therapeutic innovations aligned with rapidly expanding global markets Global Market Outlook & Drivers • Global CNS treatment market is projected to grow at an 8.6% CAGR, reaching $285.7 billion by 2035.¹ • Global brain tumor drugs market is expected to grow at a 9.3% CAGR, reaching $5.2 billi

  55. Slide 55: Middle East expansion plan

    MIDDLE EAST Middle East expansion plan Sources: NEO212 is an investigational product candidate. It has not been approved by the FDA or any other regulatory authority, and it s s afety and efficacy have not been established. This slide contains forward - looking statements within the meaning of Secti

  56. Slide 56: SilicoVitro technology acquisition

    3D Bioprinting (McMaster) AI Drug Modeling (USC) » Creates realistic human tumor organoids » Models neurodegenerative diseases like Alzheimer’s & Parkinson’s » Produces organoids for liver, lung, and kidney » Replaces animal models in preclinical testing Impact: Enhances accuracy and predictability

  57. Slide 57: Intellectual property

    INTELLECTUAL PROPERTY Our expanding global patent portfolio supports a competitive position U.S. Patents 32 issued 19 pending International Patents 97 issued 31 pending Protected under exclusive global licensing agreement with USC. NEO is a proprietary platform Protected by patents in the U.S., Cana

NeOnc Technologies Holdings — Investor Presentation (November 2026) on 6ix